Zika vaccine-blocker candidate being tested in animals

By Melissa Fassbender

- Last updated on GMT

Human trials may begin as early as July 2016. (Image: iStock)
Human trials may begin as early as July 2016. (Image: iStock)
Replikins’ genomic understanding of the Zika and Flaviviruses has led to the development of a trivalent vaccine for Zika, Dengue, and Japanese Encephalitis. 

The company announced its understanding of how the virus gene structures in Zika and closely related Flaviviruses evolves, earlier this week.

According to the company, a trivalent Zika-Dengue-Japanese Encephalitis Replikins Synthetic Blocker-Vaccine™ candidate has been designed and manufactured by Replikins Ltd., and is now being tested.

A Zika Gene Synthetic Replikins Vaccine-Blocker candidate has been formulated and manufactured, and is now in animal trials. Trials in humans may begin as early as July 2016​,” Samuel Bogoch,M.D.,Ph.D., chairman, Replikins Ltd., told Outsourcing-Pharma.com.

The new vaccine candidate is based on findings from Drs. Samuel and Elenore Bogoch of Boston University School of Medicine, the Foundation for Research on the Nervous System, and Replikins Ltd.

Though their research, the doctors found conserved Replikins gene sequences shared by three different Flaviviruses and “a suggestion of transfer​” of Replikins over time between the viruses. (Replikins are a group of peptides, which when increased in concentration in a virus is associated with rapid replication).

The company previously reported in January that sequences in the Zika gene were at the highest levels observed since 1947. The company used its genomic disease surveillance software to analyze the concentration and evolution changes in the genomes.

The company will report results from animal testing of the trivalent vaccine candidate as they become available.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars